TY - JOUR
T1 - Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia
AU - Bamopoulos, Stefanos A.
AU - Batcha, Aarif M.N.
AU - Jurinovic, Vindi
AU - Rothenberg-Thurley, Maja
AU - Janke, Hanna
AU - Ksienzyk, Bianka
AU - Philippou-Massier, Julia
AU - Graf, Alexander
AU - Krebs, Stefan
AU - Blum, Helmut
AU - Schneider, Stephanie
AU - Konstandin, Nikola
AU - Sauerland, Maria Cristina
AU - Görlich, Dennis
AU - Berdel, Wolfgang E.
AU - Woermann, Bernhard J.
AU - Bohlander, Stefan K.
AU - Canzar, Stefan
AU - Mansmann, Ulrich
AU - Hiddemann, Wolfgang
AU - Braess, Jan
AU - Spiekermann, Karsten
AU - Metzeler, Klaus H.
AU - Herold, Tobias
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Previous studies demonstrated that splicing factor mutations are recurrent events in hematopoietic malignancies with both clinical and functional implications. However, their aberrant splicing patterns in acute myeloid leukemia remain largely unexplored. In this study, we characterized mutations in SRSF2, U2AF1, and SF3B1, the most commonly mutated splicing factors. In our clinical analysis of 2678 patients, splicing factor mutations showed inferior relapse-free and overall survival, however, these mutations did not represent independent prognostic markers. RNA-sequencing of 246 and independent validation in 177 patients revealed an isoform expression profile which is highly characteristic for each individual mutation, with several isoforms showing a strong dysregulation. By establishing a custom differential splice junction usage pipeline, we accurately detected aberrant splicing in splicing factor mutated samples. A large proportion of differentially used junctions were novel, including several junctions in leukemia-associated genes. In SRSF2(P95H) mutants, we further explored the possibility of a cascading effect through the dysregulation of the splicing pathway. Furthermore, we observed a validated impact on overall survival for two junctions overused in SRSF2(P95H) mutants. We conclude that splicing factor mutations do not represent independent prognostic markers. However, they do have genome-wide consequences on gene splicing leading to dysregulated isoform expression of several genes.
AB - Previous studies demonstrated that splicing factor mutations are recurrent events in hematopoietic malignancies with both clinical and functional implications. However, their aberrant splicing patterns in acute myeloid leukemia remain largely unexplored. In this study, we characterized mutations in SRSF2, U2AF1, and SF3B1, the most commonly mutated splicing factors. In our clinical analysis of 2678 patients, splicing factor mutations showed inferior relapse-free and overall survival, however, these mutations did not represent independent prognostic markers. RNA-sequencing of 246 and independent validation in 177 patients revealed an isoform expression profile which is highly characteristic for each individual mutation, with several isoforms showing a strong dysregulation. By establishing a custom differential splice junction usage pipeline, we accurately detected aberrant splicing in splicing factor mutated samples. A large proportion of differentially used junctions were novel, including several junctions in leukemia-associated genes. In SRSF2(P95H) mutants, we further explored the possibility of a cascading effect through the dysregulation of the splicing pathway. Furthermore, we observed a validated impact on overall survival for two junctions overused in SRSF2(P95H) mutants. We conclude that splicing factor mutations do not represent independent prognostic markers. However, they do have genome-wide consequences on gene splicing leading to dysregulated isoform expression of several genes.
UR - http://www.scopus.com/inward/record.url?scp=85085134200&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085134200&partnerID=8YFLogxK
U2 - 10.1038/s41375-020-0839-4
DO - 10.1038/s41375-020-0839-4
M3 - Article
C2 - 32358566
AN - SCOPUS:85085134200
SN - 0887-6924
VL - 34
SP - 2621
EP - 2634
JO - Leukemia
JF - Leukemia
IS - 10
ER -